Home-based transcutaneous electrical acupoint stimulation for hypertension: a randomized controlled pilot trial

被引:0
作者
Jian-Feng Tu
Li-Qiong Wang
Jun-Hong Liu
You-Sheng Qi
Zhong-Xue Tian
Yu Wang
Jing-Wen Yang
Guang-Xia Shi
Si-Bo Kang
Cun-Zhi Liu
机构
[1] Capital Medical University,Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine
[2] Dongcheng District,International Acupuncture and Moxibustion Innovation Institute
[3] Beijing University of Chinese Medicine,School of Acupuncture
[4] Chaoyang District,Moxibustion and Tuina
[5] Beijing University of Chinese Medicine,undefined
[6] Chaoyang District,undefined
[7] Nanyuan Community Health Service Center,undefined
[8] Fengtai District,undefined
来源
Hypertension Research | 2021年 / 44卷
关键词
Transcutaneous electrical acupoint stimulation; TEAS; Usual care; Hypertension; Randomized controlled trial;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this trial was to evaluate the feasibility and effect of home-based transcutaneous electrical acupoint stimulation (TEAS) in patients with hypertension. In this randomized pilot trial, patients with hypertension were randomly assigned to the TEAS group or the usual care group. Participants in the usual care group were instructed to continue taking their antihypertensive drugs and received education on lifestyle modifications. In addition, participants in the TEAS group received 4 weekly sessions of noninvasive acupoint stimulation for 12 weeks at home. The primary outcome was the change in office systolic blood pressure at week 12 from baseline. Withdrawal from the study and adverse events associated with TEAS were also recorded. Sixty patients were randomized, with 30 patients in the TEAS group, of whom 1 was lost at week 36, and 30 patients in the usual care group, of whom 3 were lost by week 12. The reduction in systolic blood pressure at week 12 was greater in the TEAS group (−8.53 mm Hg; 95% CI [−13.37, −3.70 mm Hg]) than in the usual care group (−1.70 mm Hg; 95% CI [−4.29, −0.89 mm Hg]), with a between-group difference of −6.83 mm Hg (95% CI, [−12.23, −1.43 mm Hg]; P = 0.014). No TEAS-related adverse events occurred. In conclusion, home-based TEAS added to usual care for patients with hypertension was acceptable and safe and may be a potential treatment option. A larger randomized controlled trial of this intervention is warranted.
引用
收藏
页码:1300 / 1306
页数:6
相关论文
共 129 条
[1]  
Lewington S(2002)Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-13
[2]  
Clarke R(2012)A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2224-60
[3]  
Qizilbash N(2016)Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association Circulation 133 e38-360
[4]  
Peto R(2018)2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J 39 3021-104
[5]  
Collins R(2018)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Circulation 138 e484-484e594
[6]  
Lim SS(2015)Trends in blood pressure among adults with hypertension: United States, 2003 to 2012 Hypertension 65 54-61
[7]  
Vos T(2019)Acupuncture as adjunctive therapy for chronic stable angina: a randomized clinical trial JAMA Intern Med 179 1388-97
[8]  
Flaxman AD(2010)Acupuncture improves exercise tolerance of patients with heart failure: a placebo-controlled pilot study Heart 96 1396-400
[9]  
Danaei G(2007)Randomized trial of acupuncture to lower blood pressure Circulation 115 3121-9
[10]  
Shibuya K(2019)Acupuncture for patients with mild hypertension: A randomized controlled trial J Clin Hypertens 21 412-20